This site is intended for Healthcare professionals only.

First: Ultrathin Orsiro Stent found Better than Xience Stent, gets USFDA Nod

First: Ultrathin Orsiro Stent found Better than Xience Stent, gets USFDA Nod

New Delhi: Stent maker BIOTRONIK  has announced FDA approval of its ultrathin Stent- Orsiro drug-eluting stent (DES) system. This comes as Orsiro is the first and only ultrathin DES to outperform the clinical standard, Xience.

“Orsiro has set a new standard for safety and efficacy clinical endpoints, including statistically lower target lesion revascularization and target vessel MI rates,” said Dr. David Kandzari, BIOFLOW-V US principal investigator, Piedmont Heart Institute, Atlanta. “BIOFLOW-V data are the best clinical outcomes witnessed with modern DES. It was largely thought that efficacy findings were unsurpassable, but Orsiro proves we can further reduce event rates with meaningful innovation.”

The stent showed an unprecedented clinical performance in the BIOFLOW-V pivotal trial where demonstrated significantly lower rates for target lesion failure (TLF) and target vessel myocardial infarction (MI) at 12 months in comparison to Xience in a large, complex patient population (n=1,344).

At two years, treatment with Orsiro further improved event rates in comparison to Xience, including a significant reduction in target lesion revascularization (TLR) and spontaneous MI. The two year results presented at TCT 2018 and published in  the Journal of the American College of Cardiology of Cardiology show a 37 percent lower TLF rate in favor of Orsiro (7.5 percent versus 11.9 percent TLF rate, p-value=0.015), a 47 percent lower ischemia-driven TLR rate, and a 70 percent lower rate of spontaneous MI (landmark analysis 31 days to two years follow-up).3

For use in percutaneous coronary intervention (PCI) procedures, the cobalt chromium metal stent elutes sirolimus via BIOlute™, BIOTRONIK’s bioabsorbable polymer coating. Beneath the bioabsorbable layer is BIOTRONIK’s proBIO™, a passive coating on the bare metal surface, designed to reduce nickel ion release.

The Orsiro stent system provides ultrathin stent struts without compromising radial strength, and a low crossing profile for easier lesion cross in complex PCI.4 It is available in 52 sizes ranging from 2.25 to 4.0 mm in diameter and lengths up to 40 mm, the longest available in the United States.5

“The FDA approval of Orsiro changes the dynamic of what had become a highly commoditized DES market,” said Ryan Walters, President at BIOTRONIK, Inc. “We designed Orsiro for use even in challenging cases with features that make it unlike any other DES in the world. Hospital administrators now have available a DES that shows improved clinical event rates and interventionalists can rely on Orsiro’s deliverability to treat complex lesions6 and challenging subgroups to achieve unprecedented patient outcomes. Patients, physicians and health systems deserve the best, and that is exactly what we are bringing to the US market.”

Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted